The Uromigos

The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.

ASCO GU
image header

View our exclusive coverage of The Uromigos Live & Unplugged in Nashville, Tennessee, held September 30 through October 1, including panel discussions with experts on kidney, prostate, and bladder cancers.

Advertisement

Latest Episode

Episode 216: ADCs in Bladder Cancer
Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer, including enfortumab vedotin (EV) and the results of the drug’s EV-301 trial. The combination treatment of EV and pembrolizumab versus chemotherapy alone is also discussed, including the EV-302 trial. ...
Advertisement

ESMO Coverage

Paper of the Month

Dr. Brian Rini’s Disclosures

Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis

Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai

Stock: PTC therapeutics

Advertisement
Advertisement